Vasopressin Emerges as Hormone of Interest in Autism Research

Ask a physician what the hormone vasopressin is good for, and she will explain that it regulates the volume of water in your body and also affects blood pressure. But since the 1990s, vasopressin has been a hot topic in a very different field: social behavior. And recently it has emerged as a possible target for treating autism spectrum disorders (ASD), which are characterized by social, behavioral and communication impairments. The research is still in early stages, however, and has yielded more questions than answers.

Given that one out of 68 children in the U.S. has an autism spectrum disorder, researchers are scrambling to figure out what in the brain might be related to the symptoms, and how they might design an effective treatment. Vasopressin may be a key player in the disorder. But scientists do not yet know whether too much or too little of the hormone—or perhaps some combination of both—is tied to autism. New clinical trials may yield insights. “I think that the work is exciting and important” says Suma Jacob, who leads an autism research laboratory at the University of Minnesota. “I also think we still have a lot more work to do in this field as a whole.”

How vasopressin relates to autism

What’s more, vasopressin has also been linked to . Vasopressin neurons in the olfactory system may modulate input, sending information about smells to behavioral areas of the brain. Other senses also show connections to vasopressin, though they have been less thoroughly studied. For instance, some research found that people who received intranasal vasopressin showed an improvement in auditory recall. In a review article published in Janet Bester-Meredith of Seattle Pacific University and her colleagues explained that the effect probably stems from the hormone’s ability to increase arousal. “Vasopressin may be essential for integration of sensory input during complex forms of social behavior in mammals,” they wrote. This connection is relevant to autism because the condition can cause sensory overload and difficulty processing sensory information.

A study published strengthens the theorized connection between vasopressin and autism. A team of Stanford University researchers compared the blood levels of vasopressin in children with autism, their siblings who don’t have autism, and a control group of unrelated children who do not have autism.

The study found varying vasopressin levels in all three groups, meaning vasopressin by itself does not determine autism. However, this biomarker did predict how well children in the autism group performed on a test of “Theory of Mind” – the ability to perceive the perspectives of others. Specifically, autistic children with low vasopressin levels performed poorly on this test. In children without autism, low vasopressin levels were not linked to worse results.

“These findings also suggest that AVP [vasopressin] biology may be a promising therapeutic target by which to improve social cognition in individuals with ASD,” the researchers wrote in their study. Stanford is now that administers vasopressin as a nasal spray to test the therapeutic potential.

But other investigators suspect that increasing vasopressin has the opposite effect, worsening social function in people with autism spectrum disorders. An ongoing clinical trial by Swiss pharmaceutical giant Roche, called VANILLA, is testing a compound that blocks the overactivity of a vasopressin receptor called V1a, which has been associated with the core symptoms of autism, according to Štěpán Kráčala, a spokesman for Roche. Animal studies have shown that blocking this receptor can “normalize social behavior deficits” in rodent models of autism, he said in an e-mail.

The relevance of vasopressin in social behavior deficiencies may not be so simple a matter as “there’s too much” or “there’s too little.” It could be that normal function is compromised when there is any imbalance in vasopressin in the body, explains Sue Carter, director of the Kinsey Institute at Indiana University. “What we have at the moment are fragments of knowledge; not enough information to form a very strong hypothesis in either direction,” she remarks. For her part, Jacob, who is involved in the VANILLA trial, is eager to see the results of both the Stanford and Roche trials. “There are many feedback systems, so the pathways are never as linear as we'd prefer when we investigate them,” she notes.

Researchers are also studying oxytocin’s potential for treating autism and other social disorders. But as with vasopressin, it is not clear that more of the hormone is always better. “Some people respond in a beneficial way to oxytocin administration, other people show no real effect, and other people actually show a detrimental effect,” says social psychologist Jennifer Bartz, who studies oxytocin at McGill University.

Furthermore, both of these “love hormones” could actually be interacting with each other in important ways in social disorders such as autism, Carter says. This potential interaction deserves further study. Researchers also need to take into account that people with autism spectrum disorder vary widely in their degree of disability, she notes. Those with more mild cases can live fully independent lives, whereas those affected more severely need constant care. And symptoms differ from person to person. How vasopressin and oxytocin factor into the many manifestations of autism remains to be determined.

see also: